AVIEW vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AVIEW

by Coreline Soft Co.

EchoNext

by Pathway Labs

AI Verdict

AVIEW and EchoNext are adjacent competitors in the cardiology AI space, both offering FDA-cleared solutions. AVIEW focuses on comprehensive analysis of CT scans for multiple conditions including coronary artery calcification, while EchoNext specializes in detecting hidden structural heart disease from standard ECGs. Therefore, the choice between them depends on whether the primary need is multi-modal CT analysis or early ECG-based screening for structural heart disease.

Choose AVIEW if…

Choose AVIEW if your practice focuses on comprehensive thoracic imaging analysis, particularly for lung cancer screening, COPD assessment, and coronary artery calcification from CT scans. It excels in providing detailed AI-powered quantification, 3D visualizations, and workflow automation for radiology departments managing a high volume of CT studies.

View AVIEW →

Choose EchoNext if…

Choose EchoNext if your primary goal is early, non-invasive screening for hidden structural heart disease using standard ECGs. This tool is ideal for broad access settings, from hospitals to community practices, to identify patients at risk for conditions like heart failure, valve disease, and pulmonary hypertension, who might otherwise go undiagnosed until symptomatic.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AVIEW	EchoNext
Pricing	Subscription; one-off payment	Starts at $600/month
Deployment	Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker)	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AVIEW

AVIEW offers a broader range of deployment options (cloud, hybrid, local hardware, virtualized), suggesting greater flexibility for integration into diverse existing clinical IT environments. While EchoNext is available through the OpenEvidence platform, AVIEW's multiple deployment methods likely provide more tailored usability for different institutional needs and preferences.

Clinical Value

AVIEW

AVIEW provides comprehensive solutions for lung cancer, COPD, and coronary artery calcification from CT scans, offering detailed quantification, 3D visualizations, and follow-up capabilities. EchoNext focuses on detecting hidden structural heart disease from ECGs. While both offer significant clinical value, AVIEW's multi-organ, multi-disease diagnostic and monitoring capabilities across a critical imaging modality (CT) suggest a broader and deeper impact on patient care and diagnostic workflows.

Pricing & Value

Tie

AVIEW offers subscription and one-off payment models based on installations or users, providing flexibility. EchoNext has tiered monthly pricing starting at $600, with discounts and add-ons. Without specific pricing details for AVIEW or a clear understanding of the feature sets included at each price point for both, it's difficult to definitively determine which offers better value. Both appear to have flexible pricing structures.

Enterprise Readiness

AVIEW

AVIEW explicitly mentions workflow automation and integration with PACS/RIS/CIS, along with multiple deployment options (cloud, hybrid, local hardware, virtualized). This indicates a strong focus on seamless integration into complex enterprise healthcare IT infrastructures. EchoNext's deployment through a specific platform (OpenEvidence) might limit its direct enterprise integration flexibility compared to AVIEW's broader approach.

Innovation

AVIEW

AVIEW's feature set includes advanced capabilities like AI-powered lung nodule characterization with Lung-RADS scoring, emphysema quantification, coronary artery calcium scoring, automated segmentation, and ILD pattern analysis. This comprehensive suite of quantitative and qualitative analyses across multiple pathologies from CT scans demonstrates a higher degree of innovative application of AI in medical imaging compared to EchoNext's focus on ECG analysis for structural heart disease.

Support & Docs

Tie

Neither tool's provided information or readily available web search results offer specific details about their support services, documentation quality, or training programs. Without this crucial information, it is impossible to distinguish between the two on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AVIEW	EchoNext
Name	AVIEW	EchoNext
Company	Coreline Soft Co.	Pathway Labs
Description	Coreline Soft's AVIEW AI platform offers comprehensive solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans, enhancing diagnostic precision and streamlining radiology workflows.	EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Categories	Cardiology AI, Oncology AI, Radiology & Imaging AI	Cardiology AI, Clinical Decision Support & Reference, Lab & Diagnostics
Specialties	Cardiology, Pulmonology, Radiology	Cardiology, Family Medicine, Hospital Medicine, Internal Medicine
Key Features	AI-powered lung nodule detection and characterization (size, volume, type, location, Lung-RADS score); Emphysema quantification and low attenuation area (LAA) analysis; Coronary artery calcium (CAC) scoring (Agatston, volume, mass score, risk stratification); Automated segmentation of lung lobes, airways, vessels, and coronary arteries; 3D visualizations and comprehensive PDF reports; Workflow automation and integration with PACS/RIS/CIS; Follow-up registration and nodule matching for serial CT scans; Interstitial Lung Disease (ILD) pattern analysis (AVIEW Lung Texture)	AI-powered ECG analysis; Detection of hidden structural heart disease; Identifies heart failure risk; Screens for valve disease; Detects pulmonary hypertension indicators; Utilizes standard 12-lead ECGs; FDA-cleared technology; Non-invasive diagnostic support

Videos

Demos, reviews, and walkthroughs featuring AVIEW and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows for physicians?

AVIEW is designed to integrate with PACS/RIS/CIS systems, offering workflow automation and generating comprehensive PDF reports and 3D visualizations. EchoNext integrates with the OpenEvidence clinical decision support platform, aiming to embed its screening output directly into tools many physicians already use during patient visits, rather than requiring a separate workflow or system.

What is the accuracy and sensitivity of each tool in detecting relevant conditions?

AVIEW has demonstrated high detection sensitivity (u2265 83%) for lung nodules and 99.2% accuracy for coronary artery calcification. EchoNext, in studies, identified structural heart problems with 77% accuracy, outperforming cardiologists who had 64% accuracy when reading the same ECGs.

What is the typical learning curve for physicians adopting these AI tools?

AVIEW aims to streamline radiology workflows and reduce interpretation time, suggesting a focus on efficiency once integrated. EchoNext is designed to integrate directly into existing clinical decision support platforms like OpenEvidence, which may minimize the need for extensive new training as it aims to be 'fast, automatic, and invisible' with no new viewers or additional clicks.

What kind of clinical impact or time-to-value can a practice expect from implementing these tools?

AVIEW has shown an 89% increase in case throughput and a 60% reduction in interpretation time for radiologists. EchoNext has been credited with detecting previously undiagnosed heart failure, leading to a heart transplant in one peer-reviewed case, and aims to prompt earlier intervention and more targeted referrals for structural heart disease.

What are the considerations for rolling out these tools across multiple clinical sites?

AVIEW is built to apply the same detection algorithms and measurement protocols across all sites, aiming to eliminate variability and provide a standardized quality baseline for hospital groups and radiology networks. EchoNext's integration with OpenEvidence targets broad access for both major hospitals and community practices, suggesting scalability for multi-site deployments.

What audit-trail features are available to ensure transparency and accountability in AI-assisted diagnoses?

AVIEW's integration with platforms like mint Lesion supports structured reporting and longitudinal nodule management with full audit documentation. EchoNext's deployment through OpenEvidence and its integration into clinical workflows suggest that its outputs would be part of the patient's record, though specific audit-trail features beyond HIPAA compliance are not detailed.

Are there customer references or real-world validation examples available for these tools?

AVIEW has processed over 2.5 million cases across 19 countries and is used in major U.S. medical centers like UMass Memorial Medical Center and Temple Lung Center, as well as government-led lung cancer screening programs in Europe. EchoNext was trained on over 700,000 paired ECGs and echocardiograms from the NewYork-Presbyterian health system and validated in studies across more than 20 hospitals and 500,000 patients in the U.S. and Canada.